NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02470585,"Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",https://clinicaltrials.gov/study/NCT02470585,VELIA,TERMINATED,The primary objective of the study was to evaluate whether progression-free survival (PFS) was prolonged with the addition of veliparib to standard platinum-based chemotherapy (carboplatin/paclitaxel \[C/P\]) and continued as maintenance therapy compared with chemotherapy alone.,YES,Ovarian Cancer|Ovarian Neoplasm,DRUG: Veliparib|DRUG: Paclitaxel|DRUG: Carboplatin|OTHER: Placebo to Veliparib,"Progression-Free Survival (PFS) in the BRCA-deficient Population (Arm 3 vs Arm 1), PFS was defined as the time from the date that the participant was randomized to the date the participant experienced an event of disease progression, according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 (as determined by the investigator) or to the date of death if disease progression was not reached. If the participant did not have an event of disease progression or death prior to the analysis cut-off date, the participant's data were censored at the date of their last evaluable disease assessment. PFS was estimated using the Kaplan-Meier method. The analysis of PFS occurred when the protocol-specified number of PFS events was reached.

Progressive Disease (PD): At least a 20% increase in the size of target lesions, compared with the smallest size recorded since the treatment started, and an absolute increase of ≥ 5 mm, or unequivocal progression of existing non-target lesions or the appearance of new lesions., From randomization until the primary analysis data cut-off date of 03 May 2019, the median duration of follow-up was 28 months.|Progression-Free Survival (PFS) in the Homologous Recombination Deficiency Cohort (Arm 3 vs Arm 1), PFS was defined as the time from the date that the participant was randomized to the date the participant experienced an event of disease progression, according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 (as determined by the investigator) or to the date of death if disease progression was not reached. If the participant did not have an event of disease progression or death, the participant's data were censored at the date of their last evaluable disease assessment. PFS was estimated using the Kaplan-Meier method. The primary analysis of PFS occurred when the protocol-specified number of PFS events was reached and was performed in 3 sequentially inclusive populations.

Progressive Disease (PD): At least a 20% increase in the size of target lesions, compared with the smallest size recorded since the treatment started, and an absolute increase of ≥ 5 mm, or unequivocal progression of existing non-target lesions or the appearance of new lesions.

., From randomization until the primary analysis data cut-off date of 03 May 2019, the median duration of follow-up was 28 months.|Progression-Free Survival (PFS) in the Intention-to-treat Population (Arm 3 vs Arm 1), PFS was defined as the time from the date that the participant was randomized to the date the participant experienced an event of disease progression, according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 (as determined by the investigator) or to the date of death (all causes of mortality) if disease progression was not reached. If the participant did not have an event of disease progression according to RECIST criteria (as or death, the participant's data were censored at the date of their last evaluable disease assessment. PFS was estimated using the Kaplan-Meier method.

Progressive Disease (PD): At least a 20% increase in the size of target lesions, compared with the smallest size recorded since the treatment started, and an absolute increase of ≥ 5 mm, or unequivocal progression of existing non-target lesions or the appearance of new lesions.

The primary analysis of PFS occurred when the protocol-specified number of PFS events was reached., From randomization until the primary analysis data cut-off date of 03 May 2019, the median duration of follow-up was 28 months.","Progression-Free Survival (PFS) in the BRCA-deficient Population (Arm 2 vs Arm 1), PFS was defined as the time from the date that the participant was randomized to the date the participant experienced an event of disease progression, according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 (as determined by the investigator) or to the date of death if disease progression was not reached. If the participant did not have an event of disease progression or death prior to the analysis cut-off date, the participant's data were censored at the date of their last evaluable disease assessment. PFS was estimated using the Kaplan-Meier method. The analysis of PFS occurred when the protocol-specified number of PFS events was reached.

Progressive Disease (PD): At least a 20% increase in the size of target lesions, compared with the smallest size recorded since the treatment started, and an absolute increase of ≥ 5 mm, or unequivocal progression of existing non-target lesions or the appearance of new lesions., From randomization until the primary analysis data cut-off date of 03 May 2019, the median duration of follow-up was 28 months.|Progression-Free Survival (PFS) in the Homologous Recombination Deficiency Cohort (Arm 2 vs Arm 1), PFS was defined as the time from the date that the participant was randomized to the date the participant experienced an event of disease progression, according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 (as determined by the investigator) or to the date of death if disease progression was not reached. If the participant did not have an event of disease progression or death, the participant's data were censored at the date of their last evaluable disease assessment. PFS was estimated using the Kaplan-Meier method. The primary analysis of PFS occurred when the protocol-specified number of PFS events was reached and was performed in 3 sequentially inclusive populations.

Progressive Disease (PD): At least a 20% increase in the size of target lesions, compared with the smallest size recorded since the treatment started, and an absolute increase of ≥ 5 mm, or unequivocal progression of existing non-target lesions or the appearance of new lesions.

., From randomization until the primary analysis data cut-off date of 03 May 2019, the median duration of follow-up was 28 months.|Progression-Free Survival (PFS) in the Intention-to-treat Population (Arm 2 vs Arm 1), PFS was defined as the time from the date that the participant was randomized to the date the participant experienced an event of disease progression, according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 (as determined by the investigator) or to the date of death (all causes of mortality) if disease progression was not reached. If the participant did not have an event of disease progression according to RECIST criteria (as or death, the participant's data were censored at the date of their last evaluable disease assessment. PFS was estimated using the Kaplan-Meier method.

Progressive Disease (PD): At least a 20% increase in the size of target lesions, compared with the smallest size recorded since the treatment started, and an absolute increase of ≥ 5 mm, or unequivocal progression of existing non-target lesions or the appearance of new lesions.

The primary analysis of PFS occurred when the protocol-specified number of PFS events was reached., From randomization until the primary analysis data cut-off date of 03 May 2019, the median duration of follow-up was 28 months.|Overall Survival (OS) in the BRCA-deficient Population, OS is defined as the time from the day the participant was randomized to the date of death, and was calculated using Kaplan-Meier methods. All events of death will be included, regardless of whether the event occurs while the participant is still taking study drug, or after discontinuation of study drug. If a participant has not died, then the data will be censored at the date the participant is last known to be alive., From the time of randomization to the end of the study, up to 98 months|Overall Survival (OS) in the Homologous Recombination Deficiency Population, OS is defined as the time from the day the participant was randomized to the date of death, and was calculated using Kaplan-Meier methods. All events of death will be included, regardless of whether the event occurs while the participant is still taking study drug, or after discontinuation of study drug. If a participant has not died, then the data will be censored at the date the participant is last known to be alive., From the time of randomization to the end of the study, up to 98 months|Overall Survival (OS) in the Whole Population, OS is defined as the time from the day the participant was randomized to the date of death, and was calculated using Kaplan-Meier methods. All events of death will be included, regardless of whether the event occurs while the participant is still taking study drug, or after discontinuation of study drug. If a participant has not died, then the data will be censored at the date the participant is last known to be alive., From the time of randomization to the end of the study, up to 98 months|Change From Baseline in Disease Related Symptom (DRS) Score in the BRCA-mutation Population, The Disease Related Symptom score is a subset of the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy Ovarian Symptom Index-18 (NFOSI-18), which evaluates nine symptoms related to ovarian cancer. The NFOSI-18 DRS score ranges from 0 to 36, with higher scores indicating a lower burden of symptoms and a score of 0 being severely symptomatic. A 3-point difference was defined as clinically meaningful. A positive change from Baseline indicates improvement.

Change from Baseline was calculated using a used a mixed-model for repeated measures (MMRM) with treatment, stratification factors of residual disease and stage of disease, time point and treatment-by-time point interaction as fixed effect factors, and Baseline DRS score as a covariate.

DRS was not included in the fixed-sequence testing procedure., Baseline and Day 1 of Cycles 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, and 35|Change From Baseline in Disease Related Symptom (DRS) Score in the HRD Population, The Disease Related Symptom score is a subset of the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy Ovarian Symptom Index-18 (NFOSI-18), which evaluates nine symptoms related to ovarian cancer. The NFOSI-18 DRS score ranges from 0 to 36, with higher scores indicating a lower burden of symptoms and a score of 0 being severely symptomatic. A 3-point difference was defined as clinically meaningful. A positive change from Baseline indicates improvement.

Change from Baseline was calculated using a used a mixed-model for repeated measures (MMRM) with treatment, stratification factors of residual disease and stage of disease, time point and treatment-by-time point interaction as fixed effect factors, and Baseline DRS score as a covariate.

DRS was not included in the fixed-sequence testing procedure., Baseline and Day 1 of Cycles 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, and 35|Change From Baseline in Disease Related Symptom (DRS) Score in the Whole Population, The Disease Related Symptom score is a subset of the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy Ovarian Symptom Index-18 (NFOSI-18), which evaluates nine symptoms related to ovarian cancer. The NFOSI-18 DRS score ranges from 0 to 36, with higher scores indicating a lower burden of symptoms and a score of 0 being severely symptomatic. A 3-point difference was defined as clinically meaningful. A positive change from Baseline indicates improvement.

Change from Baseline was calculated using a used a mixed-model for repeated measures (MMRM) with treatment, stratification factors of residual disease, stage of disease, choice of paclitaxel dosing regimen and BRCA-deficient status, time point and treatment-by-time point interaction as fixed effect factors, and Baseline DRS score as a covariate.

DRS was not included in the fixed-sequence testing procedure., Baseline and Day 1 of Cycles 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, and 35",,AbbVie,Australia New Zealand Gynaecological Oncology Group,FEMALE,"ADULT, OLDER_ADULT",PHASE3,1140,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",M13-694|2014-005070-11,2015-07-14,2019-05-03,2023-10-05,2015-06-12,2020-09-14,2024-10-26,"University of Alabama at Birmingham - Main /ID# 138087, Birmingham, Alabama, 35233, United States|Tennessee Valley Gyn-Onc /ID# 139548, Huntsville, Alabama, 35805, United States|University of South Alabama /ID# 138091, Mobile, Alabama, 36604-3302, United States|Alaska Womens Cancer Care /ID# 138231, Anchorage, Alaska, 99508-4684, United States|Arizona Oncology Associates, PC-HOPE /ID# 142002, Tucson, Arizona, 85711-2701, United States|Arizona Oncology Associates, PC-HOPE /ID# 143805, Tucson, Arizona, 85711-2701, United States|Arizona Oncology Associates, PC-HOPE /ID# 143806, Tucson, Arizona, 85711-2701, United States|Arizona Oncology Associates, PC-HOPE /ID# 143808, Tucson, Arizona, 85711-2701, United States|University of Arizona Cancer Center - North Campus /ID# 138084, Tucson, Arizona, 85719-1478, United States|University of Arizona Cancer Center - North Campus /ID# 139495, Tucson, Arizona, 85719-1478, United States|University of Arkansas for Medical Sciences /ID# 138253, Little Rock, Arkansas, 72205, United States|John Muir Medical Center /ID# 139618, Concord, California, 94520, United States|Ucsd /Id# 140323, La Jolla, California, 92093, United States|Long Beach Memorial Medical Ct /ID# 147526, Long Beach, California, 90806, United States|Kaiser Permanente /ID# 141305, Los Angeles, California, 90027, United States|University of California, Los Angeles /ID# 138179, Los Angeles, California, 90095, United States|Medical Oncology Care Assoc /ID# 139498, Orange, California, 92868-4304, United States|Univ CA, Irvine Med Ctr /ID# 139613, Orange, California, 92868, United States|UC Davis Comprehensive Cancer Center - Main /ID# 144439, Sacramento, California, 95817, United States|California Pacific Medical Ctr /ID# 138177, San Francisco, California, 94115, United States|Kaiser Permanente - San Francisco /ID# 142051, San Francisco, California, 94115, United States|Univ California, San Francisco /ID# 138178, San Francisco, California, 94143-2204, United States|Kaiser Permanente-Santa Clara /ID# 142053, Santa Clara, California, 95051-5173, United States|Stanford University School of Med /ID# 139450, Stanford, California, 94305-2200, United States|Palo Alto Medical Foundation /ID# 139452, Sunnyvale, California, 94086, United States|Kaiser Permanente Medical Ctr-Vallejo /ID# 139492, Vallejo, California, 94589-2441, United States|Kaiser Permanente- Walnut Creek /ID# 142052, Walnut Creek, California, 94596, United States|Kaiser Permanente, Waterpark III Institute for Health Research /ID# 139499, Aurora, Colorado, 80014, United States|Univ of Colorado Cancer Center /ID# 138016, Aurora, Colorado, 80045, United States|Hartford Healthcare /ID# 138184, New Britain, Connecticut, 6053, United States|Yale University /ID# 138056, New Haven, Connecticut, 06510, United States|University of Miami /ID# 139457, Miami, Florida, 33136, United States|Women's Cancer Associates /ID# 140321, Saint Petersburg, Florida, 33701, United States|Sarasota Memorial Health Care /ID# 138180, Sarasota, Florida, 34239, United States|Moffitt Cancer Center /ID# 138061, Tampa, Florida, 33612-9416, United States|Georgia Regents University /ID# 138085, Augusta, Georgia, 30912, United States|IACT Health /ID# 138058, Columbus, Georgia, 31904-8946, United States|Memorial Health Univ Med Ctr /ID# 138019, Savannah, Georgia, 31404, United States|St. Joseph's/Candler /ID# 138090, Savannah, Georgia, 31405, United States|The Queens Medical Center /ID# 141709, Honolulu, Hawaii, 96813, United States|Kapiolani Medical Center /ID# 140319, Honolulu, Hawaii, 96826, United States|Rush University Medical Center /ID# 143491, Chicago, Illinois, 60612, United States|University of Chicago /ID# 139612, Chicago, Illinois, 60637-1443, United States|NorthShore University HealthSystem - Evanston Hospital /ID# 139451, Evanston, Illinois, 60201, United States|Sharma, Hinsdale, IL /ID# 140326, Hinsdale, Illinois, 60521, United States|Advocate Lutheran General Hosp /ID# 139489, Park Ridge, Illinois, 60068, United States|Indiana Univ School Medicine /ID# 139610, Indianapolis, Indiana, 46202, United States|Saint Vincent /ID# 139537, Indianapolis, Indiana, 46260, United States|McFarland Clinic, PC /ID# 139455, Ames, Iowa, 50010, United States|University of Iowa Hospitals and Clinics /ID# 138082, Iowa City, Iowa, 52242, United States|Univ Kansas Med Ctr /ID# 140322, Kansas City, Kansas, 66160, United States|Baptist Health Lexington /ID# 139542, Lexington, Kentucky, 40503, United States|University of Kentucky Chandler Medical Center /ID# 138060, Lexington, Kentucky, 40536, United States|Norton Cancer Institute /ID# 139567, Louisville, Kentucky, 40202-3700, United States|MMP Women's Health /ID# 139544, Portland, Maine, 04102, United States|Greater Baltimore Medical Ctr /ID# 138049, Baltimore, Maryland, 21204, United States|Sinai Hospital of Baltimore /ID# 141306, Baltimore, Maryland, 21215, United States|Weinberg Cancer Inst Franklin /ID# 138235, Rossville, Maryland, 21237, United States|Baystate Medical Center /ID# 139456, Springfield, Massachusetts, 01199, United States|UMass Memorial Medical Center /ID# 139458, Worcester, Massachusetts, 01655, United States|Wayne State University /ID# 139601, Detroit, Michigan, 48201-2013, United States|Henry Ford Health System /ID# 139536, Detroit, Michigan, 48202, United States|William Beaumont Hospital /ID# 139550, Royal Oak, Michigan, 48073-6710, United States|Mayo Clinic - Rochester /ID# 139565, Rochester, Minnesota, 55905-0001, United States|Mmcorc /Id# 139534, Saint Louis Park, Minnesota, 55416, United States|St. Dominic Hospital /ID# 138241, Jackson, Mississippi, 39216, United States|Ellis Fischel Cancer Center /ID# 139571, Columbia, Missouri, 65212-1000, United States|Washington University-School of Medicine /ID# 138089, Saint Louis, Missouri, 63110, United States|Cancer Research For the Ozarks /ID# 139538, Springfield, Missouri, 65804, United States|Ferrell-Duncan Clinic /ID# 143484, Springfield, Missouri, 65807, United States|Nebraska Methodist Hospital /ID# 139600, Omaha, Nebraska, 68114, United States|Womens Cancer Center of Nevada /ID# 138092, Las Vegas, Nevada, 89169, United States|Renown Regional Medical Center /ID# 138237, Reno, Nevada, 89502, United States|Dartmouth-Hitchcock Medical Center /ID# 139502, Lebanon, New Hampshire, 03756, United States|MD Anderson Cancer Ctr at Coop /ID# 139616, Camden, New Jersey, 08103, United States|Hackensack Univ Med Ctr /ID# 143776, Hackensack, New Jersey, 07601, United States|University of New Mexico /ID# 144220, Albuquerque, New Mexico, 87102, United States|SW Gynecologic Oncology Assoc /ID# 147097, Albuquerque, New Mexico, 87106, United States|Women's Cancer Care Associates /ID# 138234, Albany, New York, 12208, United States|Montefiore Medical Center /ID# 139585, Bronx, New York, 10461, United States|SUNY Downstate Medical Center /ID# 139533, Brooklyn, New York, 11203, United States|Roswell Park Comprehensive Cancer Center /ID# 138052, Buffalo, New York, 14263, United States|Northwell Health /ID# 139572, Lake Success, New York, 11042, United States|Icahn School of Med Mt. Sinai /ID# 139617, New York, New York, 10029, United States|Columbia University Medical Center /ID# 138252, New York, New York, 10032-3729, United States|Memorial Sloan Kettering Cancer Center /ID# 138017, New York, New York, 10065-6007, United States|Memorial Sloan Kettering Cancer Center /ID# 154464, New York, New York, 10065-6007, United States|SUNY Upstate Medical University - Downtown /ID# 139513, Syracuse, New York, 13210, United States|Hope Womens Cancer Centers /ID# 139614, Asheville, North Carolina, 28816, United States|Univ NC Chapel Hill /ID# 138547, Chapel Hill, North Carolina, 27514-4220, United States|Atrium Health Carolinas Medical Center /ID# 139568, Charlotte, North Carolina, 28203, United States|Presbyterian Cancer Center /ID# 139590, Charlotte, North Carolina, 28204, United States|Duke University Medical Center /ID# 138048, Durham, North Carolina, 27710-3000, United States|Wake Forest Baptist Medical Center /ID# 139588, Winston-Salem, North Carolina, 27157-0001, United States|University of Cincinnati /ID# 139619, Cincinnati, Ohio, 45267-0585, United States|Univ Hosp Cleveland /ID# 139615, Cleveland, Ohio, 44106, United States|Fairview Hospital /ID# 144403, Cleveland, Ohio, 44111, United States|Cleveland Clinic Main Campus /ID# 139501, Cleveland, Ohio, 44195, United States|The Ohio State University - Columbus /ID# 138053, Columbus, Ohio, 43210, United States|Columbus NCORP /ID# 139587, Columbus, Ohio, 43215, United States|Womens Cancer Center /ID# 138062, Kettering, Ohio, 45429-1226, United States|Hillcrest Hospital /ID# 144404, Mayfield Heights, Ohio, 44124, United States|Univ Oklahoma HSC /ID# 138020, Oklahoma City, Oklahoma, 73104, United States|Oklahoma Cancer Specialists /ID# 138059, Tulsa, Oklahoma, 74146, United States|Willamette Valley Cancer Institute /ID# 140318, Eugene, Oregon, 97401-6043, United States|Kaiser Permanente, NW /ID# 138249, Portland, Oregon, 97227, United States|Abington Memorial Hospital /ID# 138086, Abington, Pennsylvania, 19001, United States|University of Pennsylvania /ID# 140079, Philadelphia, Pennsylvania, 19104-5502, United States|Thomas Jefferson University /ID# 138239, Philadelphia, Pennsylvania, 19107-4414, United States|Fox Chase Cancer Center /ID# 149479, Philadelphia, Pennsylvania, 19111, United States|University of Pittsburgh MC /ID# 138054, Pittsburgh, Pennsylvania, 15260, United States|Reading Hospital /ID# 138057, Reading, Pennsylvania, 19611, United States|Women and Infants Hospital /ID# 138083, Providence, Rhode Island, 02905, United States|Medical University of South Carolina /ID# 138181, Charleston, South Carolina, 29425, United States|Sanford Research/USD /ID# 139624, Sioux Falls, South Dakota, 57104-8805, United States|Chattanoogas Program in Womens /ID# 139545, Chattanooga, Tennessee, 37403, United States|Texas Oncology - Austin Central /ID# 143817, Austin, Texas, 78731, United States|Texas Oncology - South Austin /ID# 143818, Austin, Texas, 78745, United States|Texas Oncology - Bedford /ID# 143814, Bedford, Texas, 76022, United States|Texas Oncology - Medical City Dallas /ID# 143809, Dallas, Texas, 75230, United States|Texas Oncology - Medical City Dallas /ID# 143812, Dallas, Texas, 75230, United States|Texas Oncology - Forth Worth /ID# 143811, Fort Worth, Texas, 76104-2150, United States|Houston Methodist Hospital - Scurlock Tower /ID# 138232, Houston, Texas, 77030, United States|Memorial Hermann Hospital /ID# 138238, Houston, Texas, 77030, United States|Texas Oncology - The Woodlands /ID# 142003, The Woodlands, Texas, 77380, United States|Texas Oncology - Tyler /ID# 143810, Tyler, Texas, 75702, United States|University of Utah /ID# 138250, Salt Lake City, Utah, 84112-5500, United States|University of Vermont Medical Center /ID# 138251, Burlington, Vermont, 05401-1473, United States|University of Virginia /ID# 138088, Charlottesville, Virginia, 22908, United States|Carilion Roanoke Memorial Hosp /ID# 139602, Roanoke, Virginia, 24014, United States|Skagit Valley Medical Center /ID# 139586, Mount Vernon, Washington, 98273, United States|MultiCare Regional Cancer Ctr /ID# 149872, Puyallup, Washington, 93872, United States|Multicare Institute for Research and Innovation /ID# 143485, Tacoma, Washington, 98405, United States|HSHS St. Vincent Hospital /ID# 139453, Green Bay, Wisconsin, 54301, United States|Froedtert & the Medical College of Wisconsin /ID# 139449, Milwaukee, Wisconsin, 53226-3522, United States|Coffs Harbour Health Campus /ID# 145132, Coffs Harbour, New South Wales, 2450, Australia|Gosford Hospital /ID# 145299, Gosford, New South Wales, 2250, Australia|St George Hospital /ID# 145138, Kogarah, New South Wales, 2217, Australia|Newcastle Private Hospital /ID# 145834, Lambton Heights, New South Wales, 2305, Australia|The Prince of Wales Hospital /ID# 145134, Randwick, New South Wales, 2031, Australia|Northern Cancer Institute /ID# 145681, St Leonards, New South Wales, 2065, Australia|Calvary Mater Newcastle /ID# 145139, Waratah, New South Wales, 2298, Australia|Westmead Hospital /ID# 145137, Westmead, New South Wales, 2145, Australia|Southern Medical Day Care Ctr /ID# 145133, Wollongong, New South Wales, 2500, Australia|The Townsville Hospital /ID# 149163, Douglas, Queensland, 4814, Australia|Royal Brisbane and Women's Hospital /ID# 145135, Herston, Queensland, 4029, Australia|Icon Cancer Centre /ID# 148208, South Brisbane, Queensland, 4101, Australia|Mater Misericordiae Limited /ID# 145682, South Brisbane, Queensland, 4101, Australia|Royal Adelaide Hospital /ID# 150071, Adelaide, South Australia, 5000, Australia|Monash Health /ID# 145297, Clayton, Victoria, 3168, Australia|Cabrini Health /ID# 145142, Malvern, Victoria, 3144, Australia|Royal Womens Hospital /ID# 145136, Parkville, Victoria, 3052, Australia|Sir Charles Gairdner Hospital /ID# 145140, Nedlands, Western Australia, 6009, Australia|St. John of God Subiaco Hosp /ID# 147742, Subiaco, Western Australia, 6008, Australia|Hc Ufmg /Id# 137156, Belo Horizonte, Minas Gerais, 30130-100, Brazil|Hospital Sao Lucas da PUCRS /ID# 137157, Porto Alegre, Rio Grande Do Sul, 90610-000, Brazil|Hospital de Cancer de Barretos /ID# 137121, Barretos, Sao Paulo, 14784-400, Brazil|Centro de Referencia da Saude da Mulher - Hospital Perola Byington /ID# 137120, São Paulo, Sao Paulo, 01317-000, Brazil|Instituto Nacional de Câncer José de Alencar Gomes da Silva (INCA) /ID# 137155, Rio de Janeiro, 20231-050, Brazil|Vejle Sygehus /ID# 137262, Vejle, Syddanmark, 7100, Denmark|Regionshospitalet Herning /ID# 137260, Herning, 7400, Denmark|Rambam Health Care Campus /ID# 137434, Haifa, 3109601, Israel|The Lady Davis Carmel MC /ID# 137537, Haifa, 3436212, Israel|Shaare Zedek Medical Center /ID# 137435, Jerusalem, 91031, Israel|Meir Medical Center /ID# 139397, Kfar Saba, 4428164, Israel|Sheba Medical Center /ID# 137436, Ramat Gan, 5262100, Israel|Kaplan Medical Center /ID# 137536, Rehovot, 76100, Israel|Aichi Cancer Center Hospital /ID# 148398, Nagoya-shi, Aichi, 464-8681, Japan|National Hospital Organization Kyushu Cancer Center /ID# 149133, Fukuoka-shi, Fukuoka, 811-1395, Japan|Kurume University Hospital /ID# 148697, Kurume-shi, Fukuoka, 830-0011, Japan|Iwate Medical University Hospital /ID# 147721, Shiwa-gun, Iwate, 028-3695, Japan|Kumamoto University Hospital /ID# 154169, Kumamoto-shi, Kumamoto, 860-8556, Japan|Mie University Hospital /ID# 149169, Tsu-shi, Mie, 514-8507, Japan|Tohoku University Hospital /ID# 149818, Sendai-shi, Miyagi, 980-8574, Japan|Niigata University Medical & Dental Hospital /ID# 149488, Niigata-shi, Niigata, 951-8520, Japan|Kindai University Hospital /ID# 154947, Osaka-sayama, Osaka, 5898511, Japan|Shizuoka Cancer Center /ID# 147723, Sunto-gun, Shizuoka, 411-8777, Japan|The Cancer Institute Hosp JFCR /ID# 148436, Koto-ku, Tokyo, 135-8550, Japan|Keio University Hospital /ID# 148326, Shinjuku-ku, Tokyo, 160-8582, Japan|Yamagata University Hospital /ID# 153646, Yamagata-shi, Yamagata, 990-9585, Japan|Hyogo Cancer Center /ID# 148327, Akashi, 673-8558, Japan|Kansai Rosai Hospital /ID# 149237, Amagasaki, 660-8511, Japan|The Jikei Univ. Kashiwa Hosp. /ID# 149238, Kashiwa-shi, 277-0004, Japan|St. Marianna Univ Hospital /ID# 149327, Kawasaki, 216-8511, Japan|NHO Kure Medical Center and Ch /ID# 148569, Kure, 737-0023, Japan|Shikoku Cancer Center /ID# 148382, Matsuyama, 791-0280, Japan|Osaka International Cancer Institute /ID# 150778, Osaka, 541-8567, Japan|Hokkaido Cancer Center /ID# 148570, Sapporo, 003-0804, Japan|The Jikei University Hospital /ID# 148691, Tokyo, 105-8461, Japan|National Cancer Center /ID# 139404, Goyang, Gyeonggido, 10408, Korea, Republic of|Korea University Anam Hospital /ID# 136908, 성북구, Gyeonggido, 02841, Korea, Republic of|Gangnam Severance Hospital /ID# 136835, Seoul, Seoul Teugbyeolsi, 06273, Korea, Republic of|Samsung Medical Center /ID# 136834, Seoul, Seoul Teugbyeolsi, 06351, Korea, Republic of|Seoul National University Hospital /ID# 136909, Seoul, 03080, Korea, Republic of|Asan Medical Center /ID# 136836, Seoul, 05505, Korea, Republic of|Auckland City Hospital /ID# 145123, Auckland, 1023, New Zealand|Uniwersyteckie C. Kliniczne /ID# 138021, Gdańsk, 80-214, Poland|Hospital Duran i Reynals /ID# 137298, L'Hospitalet de Llobregat, Barcelona, 08907, Spain|Hospital Univ Vall d'Hebron /ID# 137297, Barcelona, 08035, Spain|Hospital Clinic de Barcelona /ID# 137300, Barcelona, 08036, Spain|Hospital Clin Univ San Carlos /ID# 137402, Madrid, 28040, Spain|Hosp Univ 12 de Octubre /ID# 137299, Madrid, 28041, Spain|Hosp Univ Madrid Sanchinarro /ID# 137414, Madrid, 28050, Spain|Fundacion Inst Valenciano Onc /ID# 137403, Valencia, 46009, Spain|Norfolk and Norwich Univ Hosp /ID# 137969, Norwich, Norfolk, NR4 7UY, United Kingdom|Beatson west of scotland cancer center /ID# 137965, Glasgow, Scotland, G12 0YN, United Kingdom|Ninewells Hospital /ID# 137967, Dundee, DD1 9SY, United Kingdom|James Paget University Hosp /ID# 137970, Great Yarmouth, NR31 6LA, United Kingdom|Imanova Limited, Hammersmith Hospital /ID# 137966, London, W12 0HS, United Kingdom|Oxford Univ Hosp NHS Trust /ID# 137973, Oxford, OX3 7LE, United Kingdom","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/85/NCT02470585/Prot_002.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/85/NCT02470585/SAP_001.pdf"
